Key Details
Price
$5.61Annual ROE
-2.97%Beta
1.62Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 5, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
I'm upgrading Cytek Biosciences from "Hold" to "Buy" due to improving financials, expanding installed base, and strong demand for Aurora and Northern Lights systems. Cytek's Q3 FY2024 revenue up 7% YoY, driven by international demand; service revenue surged 25% YoY, boosting recurring revenue streams. The recently announced buyback plan went unnoticed, based on the EPS estimates revisions.
FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase program on December 31, 2024.
FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program.
Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.01 per share a year ago.
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure.
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Luella, and I will be your conference operator today.
Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes.
FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems.
Cytek Biosciences, Inc. (Nasdaq: CTKB), a prominent company in cell analysis solutions, is dedicated to advancing the cell analysis market through participation in important industry events globally.
Investors frequently consider the advice of Wall Street analysts before making decisions on whether to buy, sell, or hold a stock. Changes in ratings by these analysts, who are employed by brokerage firms, can impact the price of a stock based on media reports.
FAQ
- What is the ticker symbol for Cytek Biosciences?
- Does Cytek Biosciences pay dividends?
- What sector is Cytek Biosciences in?
- What industry is Cytek Biosciences in?
- What country is Cytek Biosciences based in?
- When did Cytek Biosciences go public?
- Is Cytek Biosciences in the S&P 500?
- Is Cytek Biosciences in the NASDAQ 100?
- Is Cytek Biosciences in the Dow Jones?
- When was Cytek Biosciences's last earnings report?
- When does Cytek Biosciences report earnings?
- Should I buy Cytek Biosciences stock now?